Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych MEQs / SAQsConsultation-liaison psychiatry

Psych MEQs / SAQs · Consultation-liaison psychiatry

Lupus psychosis and attribution in NPSLE (MEQ)

FRANZCP-style MEQ on lupus psychosis, ACR syndromes, attribution, EULAR-aligned management, and family communication.

20 marks20 min1 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 26-year-old woman with a 3-year history of SLE (prior arthritis and rash; on hydroxychloroquine and low-dose prednisolone) presents with 10 days of insomnia, persecutory delusions, and auditory hallucinations. Temperature is 37.4 C. There is mild proteinuria and low C3. Family insist this is 'ordinary schizophrenia' and want depot antipsychotic only. (i) List the ACR-relevant psychiatric syndromes and outline how you attribute this presentation to SLE versus alternatives. (ii) Detail investigation priorities including antibodies and infection exclusion. (iii) Describe mechanism-based definitive treatment principles (inflammatory vs thrombotic) and symptomatic psychotropic approach with one dose example. (iv) Explain communication with family and capacity/legal principles without inventing statute numbers. (20 marks)

Model answer

Reveal model answerShowHide

(i) Syndromes and attribution. ACR psychiatric-relevant CNS syndromes include psychosis, mood disorder, anxiety disorder, cognitive dysfunction, and acute confusional state among the broader 19 NP case definitions. This presentation maps to psychosis (with possible mixed mood features). Attribution to SLE is supported by known SLE, serologic activity (low C3, proteinuria), subacute tempo, and multi-system clues — but is not automatic. Exclude infection, substance use, primary psychotic disorder, steroid toxicity (if doses recently escalated), metabolic encephalopathy, and APS-related processes. Depot-only primary schizophrenia framing is premature.[1][2][3]

(ii) Investigations. Joint rheumatology/CL plan: infection screen (cultures, consider LP if meningism/ACS/fever trajectory, opportunistic pathogens as risk warrants), metabolic panel, urine, anti-dsDNA/complements, aPL panel, consider anti-ribosomal P as supportive for diffuse psychiatric NPSLE, MRI brain (may be normal/non-specific), EEG if fluctuating consciousness/seizure risk. Do not treat a normal MRI as exclusion of diffuse NPSLE.[2][3][4]

(iii) Treatment principles. If inflammatory primary NPSLE psychosis is the working attribution after infection exclusion: high-dose glucocorticoids and immunosuppression per EULAR-aligned practice (classically cyclophosphamide for severe inflammatory CNS disease under rheumatology protocol; alternatives if contraindicated/refractory). If aPL/thrombotic phenotype dominates focal vascular disease, prioritise antithrombotic care. Symptomatic: lowest-effective antipsychotic bridge, e.g. olanzapine 2.5–5 mg oral at night with metabolic/QTc monitoring, while disease-modifying therapy proceeds — psychotropics are not definitive cure.[2][3][5]

(iv) Family and capacity. Explain in plain language that immune activity can affect the brain and produce psychosis; tests exclude infection; treatment may include steroids/immunosuppression plus short-term psychiatric medicine; recovery is often good with early care but needs shared teams. Assess capacity for investigation/treatment; if lacking, use local least-restrictive legal framework for emergency care — state principles, not invented foreign section numbers. Safety plan for suicide/aggression risk.[2][3]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this meqs / saq. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes Arthritis Rheum, 1999.PMID 10211873
  2. [2]Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations Ann Rheum Dis, 2010.PMID 20724309
  3. [3]Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives Drugs, 2016.PMID 26809245
  4. [4]Isshi K, Hirohata S Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus Arthritis Rheum, 1996.PMID 8814059
  5. [5]Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Ann Rheum Dis, 2019.PMID 30926722
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousLong COVID neuropsychiatry — assessment, pacing and the disability letter (MEQ)Consultation-liaison psychiatryNextMild cognitive impairment — diagnosis, conversion, and management (MEQ)Consultation-liaison psychiatry